drugset / Trial / NCT02360397

Ranolazine Mediated PVC Reduction in Ischemic Heart Disease

NCT02360397

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether ranolazine has beneficial effects on cardiac ischemia through reduction of premature ventricular contraction burden.

Timeline

Start
2014-12
Primary completion
2017-12-31
Completion
2018-02-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranolazine Small molecule 1000 mg